Ser494
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser494  -  AMPKA1 (human)

Site Information
GtAtPQRsGsVsNyR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4717473
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , mutation of modification site ( 5 ) , phospho-antibody ( 5 ) , western blotting ( 5 )
Disease tissue studied:
leukemia ( 15 ) , chronic myelogenous leukemia ( 15 ) , lung cancer ( 1 , 2 , 3 , 4 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , non-small cell lung cancer ( 1 , 2 , 3 , 4 , 7 , 8 , 9 , 10 , 11 , 12 , 14 ) , non-small cell lung adenocarcinoma ( 1 , 2 , 3 , 4 ) , non-small cell large cell lung carcinoma ( 2 )
Relevant cell line - cell type - tissue:
293E (epithelial) ( 5 ) , Cal-12T (pulmonary) ( 4 ) , Calu-3 (pulmonary) ( 1 ) , DMS153 (pulmonary) ( 3 ) , HCC44 (pulmonary) ( 4 ) , HCC78 (pulmonary) ( 2 ) , HCC827 (pulmonary) ( 1 ) , K562 (erythroid) ( 15 ) , lung ( 1 , 2 , 3 , 4 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 ) , NCI-H1437 (pulmonary) ( 3 , 4 ) , NCI-H1650 (pulmonary) ( 1 ) , NCI-H1666 (pulmonary) ( 4 ) , NCI-H1781 (pulmonary) ( 2 ) , NCI-H1975 (pulmonary) ( 1 ) , NCI-H2073 (pulmonary) ( 3 ) , NCI-H209 (pulmonary) ( 3 ) , NCI-H2106 (pulmonary) ( 1 ) , NCI-H2228 (pulmonary) ( 2 ) , NCI-H2405 (pulmonary) ( 4 ) , NCI-H3122 (pulmonary) ( 2 ) , NCI-H661 (pulmonary) ( 2 ) , NCI-H838 (pulmonary) ( 3 )

Upstream Regulation
Putative in vivo kinases:
Akt1 (human) ( 5 )
Kinases, in vitro:
AMPKA1 (human) ( 16 )
Treatments:
insulin ( 5 )

Downstream Regulation
Effects of modification on AMPKA1:
phosphorylation ( 5 )

References 

1

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

2

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Suzuki T, et al. (2013) Inhibition of AMPK catabolic action by GSK3. Mol Cell 50, 407-19
23623684   Curated Info

6

Rikova K (2011) CST Curation Set: 13119; Year: 2011; Biosample/Treatment: cell line, MGH-7/unknown; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

7

Rikova K (2010) CST Curation Set: 9452; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

8

Rikova K (2010) CST Curation Set: 9461; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

9

Rikova K (2010) CST Curation Set: 9455; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

10

Rikova K (2010) CST Curation Set: 9468; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

11

Rikova K (2010) CST Curation Set: 9453; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

12

Rikova K (2010) CST Curation Set: 9454; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

13

Rikova K (2010) CST Curation Set: 9469; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

14

Rikova K (2010) CST Curation Set: 9466; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

15

Rikova K (2010) CST Curation Set: 9326; Year: 2010; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

16

Tuerk RD, et al. (2009) Tracking and quantification of 32P-labeled phosphopeptides in liquid chromatography matrix-assisted laser desorption/ionization mass spectrometry. Anal Biochem 390, 141-8
19376078   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.